W

ASHINGTON — For the first time in years, the medical device tax will take effect Jan. 1, after Congress left town without delivering on a long-promised delay or repeal. But opponents of the tax, both in industry and on Capitol Hill, aren’t giving up yet: They’re scrambling to find another solution that could offer some relief at the start of the new year.

Already they’ve secured commitments from congressional leaders that they will delay or repeal the 2.3 percent excise tax early in 2018. And now some lobbyists and lawmakers are working with the Treasury Department in hopes that the Trump administration will waive the penalties associated with problematic compliance in the early weeks of the year, before Congress might make good on its effort to address the tax. That will help companies whose accounting and reporting systems might not be ready for the Jan. 1 start date, an industry official said.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy